Evaluation of Massachusetts State-Mandated Pilot of MOUD in Jails (032)
Study Information
In Massachusetts, individuals returning to the community are up to 120 times more likely to experience a fatal overdose than the general population.
A 2018 Massachusetts law (“Chapter 208”) established a four-year pilot program to expand the use of all FDA-approved forms of medications for opioid use disorder (MOUD) at five county jails; two additional jails voluntarily joined this pilot. The law stipulates that MOUD be maintained for individuals who were already receiving it prior to detention; initiated prior to release from jail when appropriate; and, continued in the community via facilitated linkages to local services after release.
The Massachusetts JCOIN Research Center is conducting a longitudinal treatment outcome study of individuals in these jails to examine MOUD initiation, engagement and retention, as well as fatal and non-fatal overdose and recidivism. The study will also identify strategies associated with the successful implementation of MOUD and inform the development of future strategies to address opioid use disorder in jails nationwide.
Study Settings: Jails/Prisons
Study Location: Massachusetts
Publications:
- A qualitative study of big data and the opioid epidemic: recommendations for data governance (2020)
- Massachusetts Justice Community Opioid Innovation Network (MassJCOIN) (2021)
- COVID-19 and treating incarcerated populations for opioid use disorder (2021)
- Uncommon and preventable: Perceptions of diversion of MOUD in jail (2022)
- Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives (2022)
- Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers (2022)
- Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts (2022)
- “And Then COVID Hits”: A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19 (2023)
- COVID-19 impact on opioid overdose after jail release in Massachusetts (2023)
- Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail (2023)
- Holyoke Early Access to Recovery and Treatment (HEART): A case study of a court-based intervention to reduce opioid overdose (2023)
- Use of Big Data and Ethical Issues for Populations with Substance Use Disorder (2023)
- Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts (2023)
- Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives (2024)
- Association of random and observed urine drug screening with long-term retention in opioid treatment programs (2024)
- “Expected to happen”: perspectives on post-release overdose from recently incarcerated people with opioid use disorder (2024)
- Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study (2024)
- Receipt of MOUD before and after incarceration in Massachusetts State prisons, 2014-2019 (2024)
Grant number: UG1DA050067
Link to NIH Reporter record: https://reporter.nih.gov/project-details/9882834
Study Team
PI: Liz Evans, Peter Friedmann
• Evaluate MOUD delivery in jail and care coordination in the community
• Measure MOUD initiation, engagement, and retention in jail and in the community
• Track utilization of health services, health status, and recidivism following release from jail
• Identify best practices to scale-up the Chapter 208 pilot program
• Estimate the economic cost of implementing MOUD programs in jail
Clinical Trial, State Policy Rollout